Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy

Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, high interstitial pressure, and resistant tumor microenvironment. We have developed a combination therapy that can significantly slow the growth of large, stroma-rich tumors by causing massive apoptosis in the tumor center while simultaneously increasing nanoparticle uptake through a treatment-induced increase in the accumulation and retention of nanoparticles in the tumor. The vascular disrupting agent Combretastatin A-4 Phosphate (CA4P) is able to increase the accumulation of radiation-containing nanoparticles for internal radiation therapy, and the retention of these delivered radioisotopes is maintained over several days. We use ultrasound to measure the effect of CA4P in live tumor-bearing mice, and we encapsulate the radio-theranostic isotope 177Lutetium as a therapeutic agent as well as a means to measure nanoparticle accumulation and retention in the tumor. This combination therapy induces prolonged apoptosis in the tumor, decreasing both the fibroblast and total cell density and allowing further tumor growth inhibition using a cisplatin-containing nanoparticle.

[1]  J. Friedberg,et al.  Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. , 2016, Clinical lymphoma, myeloma & leukemia.

[2]  Leaf Huang,et al.  Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform , 2016, Theranostics.

[3]  W. Lau,et al.  Current role of selective internal radiation with yttrium-90 in liver tumors. , 2016, Future oncology.

[4]  Leaf Huang,et al.  A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[5]  William Y. Kim,et al.  Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Xuesi Chen,et al.  Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions. , 2015, Small.

[7]  A. Haug,et al.  Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[8]  William Y. Kim,et al.  Nanoparticles with Precise Ratiometric Co‐Loading and Co‐Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer , 2014, Advanced functional materials.

[9]  Yuhua Wang,et al.  Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Fan Wang,et al.  Anti-tumor Effect of Integrin Targeted 177Lu-3PRGD2 and Combined Therapy with Endostar , 2014, Theranostics.

[11]  Yuhua Wang,et al.  Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. , 2013, ACS nano.

[12]  R. Swann,et al.  Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy , 2013, Clinical Cancer Research.

[13]  Cyrus Chargari,et al.  Combination of vascular disrupting agents and ionizing radiation. , 2013, Critical reviews in oncology/hematology.

[14]  Paul A Dayton,et al.  Validation of dynamic contrast-enhanced ultrasound in rodent kidneys as an absolute quantitative method for measuring blood perfusion. , 2011, Ultrasound in medicine & biology.

[15]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[16]  Paul A Dayton,et al.  Quantitative Volumetric Perfusion Mapping of the Microvasculature Using Contrast Ultrasound , 2010, Investigative radiology.

[17]  E. Voest,et al.  Vascular disrupting agents (VDAs) in anticancer therapy. , 2010, Current clinical pharmacology.

[18]  R. Wendt Beta-ray dose kernels for Ho-166 and Lu-177 , 2010 .

[19]  D. Chaplin,et al.  A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) , 2009, Expert opinion on investigational drugs.

[20]  Stavroula Sofou Radionuclide carriers for targeting of cancer , 2008, International journal of nanomedicine.

[21]  Vicky Goh,et al.  Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[22]  P. LoRusso,et al.  Differentiation and definition of vascular-targeted therapies. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Pradeep Tyagi,et al.  Anisamide‐targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells , 2004, International journal of cancer.

[24]  C. Kanthou,et al.  The biology of the combretastatins as tumour vascular targeting agents , 2002, International journal of experimental pathology.

[25]  G. Griffiths,et al.  Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  A. Li,et al.  Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. , 1998, International journal of radiation oncology, biology, physics.

[27]  G. Tozer,et al.  Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. , 1997, Cancer research.

[28]  M. G. Honig,et al.  Dil and DiO: versatile fluorescent dyes for neuronal labelling and pathway tracing , 1989, Trends in Neurosciences.

[29]  F. Kiessling,et al.  Theranostics: Methods and Protocols , 2019, Methods in Molecular Biology.

[30]  F. Lee,et al.  Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. , 2001, Anticancer research.